Results 31 to 40 of about 3,658 (219)
The Effect of Elexacaftor/Tezacaftor/Ivacaftor on Hospitalizations and Intravenous Antibiotic Use
The Permanente Journal, 2022 Elexacaftor/tezacaftor/ivacaftor (ETI) is a highly effective cystic fibrosis transmembrane conductance regulator modulator. It has been shown to improve lung function and decrease pulmonary exacerbations in short-term clinical trials. The effect of ETI on hospitalization and intravenous (IV) antibiotic rates is not known.
Eric, Walter, Jennifer L, Bass
openaire +2 more sources
Impact of Elexacaftor–Tezacaftor–Ivacaftor on lung disease in cystic fibrosis
Pediatric Pulmonology, 2023 AbstractBackgroundIn people with cystic fibrosis (pwCF), the impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies, such as Elexacaftor–Tezacaftor–Ivacaftor (ETI), on structural changes in the lungs is unclear.ObjectiveTo determine the impact of ETI on clinical parameters and on structural lung disease as measured by ...
Courtney Gushue +6 more
openaire +2 more sources
Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease
European Respiratory Review, 2020 Drug compounds that augment the production and activity of the cystic fibrosis (CF) transmembrane regulator (CFTR) have revolutionised CF care. Many adults and some children with CF suffer advanced and severe lung disease or await lung transplantation ...
Michal Shteinberg +1 more
doaj +1 more source
Clinical Case Reports, 2021 Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane regulator (CFTR) modulator. It is known to be efficacious in stable patients with severe pneumopathy, but there are few data concerning its effectiveness during acute ...
Donatello Salvatore +4 more
doaj +1 more source
Novel CFTR modulator combinations maximise rescue of G85E and N1303K in rectal organoids
ERJ Open Research, 2022 Introduction Cystic fibrosis (CF) is a severe monogenic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Marjolein M. Ensinck +9 more
doaj +1 more source
Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)
Canadian Journal of Health Technologies, 2021 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +3 more sources
Pharmaceuticals, 2022 The use of modulator drugs that target the Cystic Fibrosis transmembrane conductance regulator (CFTR) is the final frontier in the treatment of Cystic Fibrosis (CF), a genetic multiorgan disease.
Giuseppe Migliorisi +7 more
doaj +1 more source
Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis. [PDF]
ThoraxBackground Despite significant clinical improvements, there is evidence of persisting airway inflammation in people with cystic fibrosis (CF) established on elexacaftor/tezacaftor/ivacaftor (ETI) therapy. As CF is a multi-system disease, systemic immune profiles can reflect local inflammation within the lungs and ...
Maher RE +16 more
europepmc +5 more sources
Pharmaceuticals, 2023 Cystic fibrosis (CF) is a potentially fatal monogenic disease that causes a progressive multisystemic pathology. Over the last decade, the introduction of CF transmembrane conductance regulator (CFTR) modulator drugs into clinical practice has profoundly
Mafalda Bacalhau +5 more
doaj +1 more source
Genetics and Molecular Biology, 2021 This is a descriptive cross-sectional study that aims to determine the distribution of the CFTR causing variant in a group of patients at a cystic fibrosis (CF) center in southern Brazil, as well as to describe causing variants that are treatable with ...
Eliandra da Silveira Lima +3 more
doaj +1 more source